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Abstract 
Spinal motoneurons innervating skeletal muscle were amongst the first neurons shown to require the presence of their target cells to 
develop appropriately. Isolated embryonie chick and rat motoneurons have been used to identify neurotrophic factors and cytokines 
capable of supporting the survival of developing motoneurons. Such factors include ciliary neurotrophic factor (CNTF), which is present 
physiologically in high amounts in myelinating Schwann cells of peripheral nerves, and brain-derived neurotrophic factor (BDNF) 
which is synthesized in skeletal muscle and, after peripheral nerve lesion. in Schwann cells. These factors have been further analyzed for 
their physiological significance in maintaining motoneuron function in vivo, and for their potential therapeutic usefulness in 
degenerative motoneuron disease. Both CNTF and BDNF are capable of rescuing injured facial motoneurons in newbom rats. 
Furthermore, CNTF prolongs survival and improves motor function of pmn mice, an animal model for degenerative motoneuron 
disease, by preventing degeneration of motoneuron axons and somata. Thus treatment of human motoneuron disease with neurotrophic 
factors should be possible, provided that rational means for application of these factors can be established considering also the 
appearance of potential side effects. 
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1. Introduction 
Neuromuscular disorders involving spinal mo-
toneurons are still a major challenge to both clinical and 
basic sciences as the mechanisms leading to these dis-
eases are far from understood. Different types of spinal 
muscular atrophy and inherited forms of amyotrophic lat-
eral sclerosis have been the topic of genetic analysis and 
significant progress has been made in the search for the 
genes underlying these disorders. For example, the gene 
defect responsible for X-linked bulbo-spinal muscular at-
rophy has been identified (La Spada et al. 1991) and very 
recently, defects in the Cu2+/zn2+ dependent superoxide 
dismutase gene have been found to be associated with fa-
milial cases of ALS (Rosen et al. 1993). 
However, it is still unclear whether these gene defects 
are also responsible for the majority of sporadic cases of 
ALS. Differences in histological and pathophysiological 
appearance suggest that the mechanisms leading to mo-
toneuron degeneration might differ for familial and spo-
radic ALS (Williams 1992). 
Neurotrophic factors are known to play a major role in 
supporting the survival of many neuronal populations in-
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cluding spinal motoneurons during development (for a re-
view see Oppenheim 1981). Moreover, lesion of mo-
toneurons during the early postnatal period Ieads to al-
most 100% cell death of the affected motoneurons, which 
can be successfully prevented by the addition of 
neurotrophic factors such as CNTF (Sendtner et al. 1990) 
and brain derived neurotrophic factor (Sendtner et al. 
l992b; Oppenheim et al. 1992b; Yan et al. 1992). These 
findings, together with other results indicating a physi-
ological role of these factors in the development and 
maintenance of function of motoneurons, provides impor-
tant information for the potential treatment of degenera-
tive motoneuron disorders. 
2. Results 
2.1. Effects of neurotrophic factors on embryonie mo-
toneurons 
During the period of developmental cell death many 
types of neurons including motoneurons are known to de-
pend on survival factors which are produced in the target 
tissues, i.e. in the case of motoneurons the skeletal mus-
cle. Skeletal muscle extracts are capable of supporting 
most of the motoneurons which would die in vitro ( Arak-
awa 1990) or in vivo (Oppenheim 1988). However, at-
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tempts to identify motoneuron survival factors from these 
extracts have been of limited success. 
Of the known factors, CNTF was first identified as be-
ing highly active in supporting the survival of embryonie 
chick and rat motoneurons in culture (Arakawa et al. 
1990; Magal et al. 1991 ). At concentrations of 1.5 ng/ml 
more than 60% of the originally plated neurons survived 
(EC50 0.023 ng/ml). A subsequent study has shown that 
CNTF was also active in vivo in rescuing motoneurons 
from cell death when supplied daily onto the chorioallan-
toic membrane of chick embryos from day 5 to 9 of de-
velopment (Oppenheim 1991). Basic FGF (bFGF) was 
shown to support about 50% of embryonie day 6 mo-
toneurons in culture, although the concentrations neces-
sary for maximal effects were about ten times higher than 
those of CNTF. Also insulin-like growth factor I (IGF-1) 
showed a significant survival effect at very high concen-
trations. Interestingly, when motoneurons from 15-day-
old rat embryos were isolated and kept in eulture under 
serum-free conditions, IGF-I was able to support more 
than 50% of the originally plated neurons at concentra-
tions between 10 and 100 ng/ml) (Hughes et al., 1993). In 
comparison, embryonie day 6 ehiek motoneurons need at 
least 1 J.tg/ml of IGF-1 for maximal survival rates of 15-
20%. A possible explanation for this discrepancy could be 
that the IGF-I effect on the cultured chick motoneurons is 
partially blocked by IGF-binding proteins present in 
horse serum (Prosser and McLaren 1992), which was 
used as a supplement (I 0%) to the culture medium of the 
chick motoneurons. 
Another differenee between embryonie chick and rat 
motoneurons in culture is the responsiveness to neurotro-
phins. Embryonie day 6 chick motoneurons do not re-
spond to BDNF and NT-3 under the same culture condi-
tions where CNTF and bFGF are active. However, in cul-
tures of embryonie day 15 rat motoneurons, BDNF and to 
a lesser extent also NT-3 show significant survival effects 
(Hughes et al., 1993). Also in vivo, these two factors are 
capable of rescuing motoneurons of newborn rats after 
peripherallesion (Sendtner et al. 1992b; Yan et al. 1992). 
Similarly, the nurober of spinal motoneurons surviving 
the developmental period of naturally occurring cell 
death in developing chick embryos could be increased by 
addition of brain-derived neurotrophic factor onto the 
chorioallantoic membrane (Oppenheim et al. 1992b). 
This finding contrasts with the negative effect of BDNF 
in supporting isolated embryonie chick motoneurons in 
eulture, indicating that chick motoneurons show different 
responsiveness to BDNF in vivo and in vitro under the 
given experimental conditions. 
Such a differential responsiveness in vivo and in vitro 
was also observed with bFGF. Although this factor is ac-
tive in supporting both motoneurons from chick and rat in 
vitro (Arakawa et al. 1990; Unsicker et al. 1987; Marti-
nou et al. 1992), bFGF did not show any significant sur-
vival effect on facial motoneurons after nerve lesion in 
newborn rats (M.S., unpublished Observations) or on spi-
nal motoneurons of developing chick embryos after daily 
injections onto the chorioallantoic membrane (Oppen-
heim et al. 1992a). These results, which are Contradietory 
to other reports (Dreyer et al. 1989), lea ve it open 
whether bFGF exerts a physiological function for spinal 
motoneurons in vivo. 
2. 2. The regulation of CNTF gene expression after peripheral 
nerve lesion: comparison with other neurotrophic factors 
CNTF is not expressed in the rat embryo during the 
period of naturally occurring cell death. In the adult rat, 
CNTF protein is found in the cytosol of myelinating 
Schwann cells of peripheral nerves and a subpopulation 
of glial cells within the centrat nervous system (Stöckli et 
al. 1991). In contrast, CNTF is not expressed in skeletal 
muscle, the target tissue of spinal motoneurons (Stöckli 
et al. 1989). The immunohistologicallocation of this fae-
tor in the eytosol of synthesizing eells (Sendtner et al. 
1991) and the absence of a hydrophobic Ieader sequence 
usually present in secretory molecules suggest that this 
molecule might aet as a lesion factor in adult animals. In 
contrast, BDNF exhibits the structural features typical of 
a secretory molecule (Leibrock et al. 1989). Furthermore, 
it is expressed in muscle during development when natu-
rally occurring motoneuron cell death occurs and thus 
fulfills the criteria for a target-derived neurotrophic fac-
tor (Barde 1989) for spinal motoneurons in analogy to the 
physiological role of NGF for sympathetic and dorsal 
root sensory neurons (Johnson et al. 1986). 
After facial nerve lesion in newborn rats, both BDNF 
and CNTF can rescue motoneurons from degeneration. 
However, the differences in structure and regulation of 
expression suggest that these two factors might have dif-
ferent functions on motoneurons after peripheral nerve 
lesion in adult rats. The Ievels of CNTF in the unlesioned 
peripheral nerves of the rat are extremely high (Table 1). 
Sciatic nerves from adult rats contain at least 1 J,!g CNTF 
per g wet weight (Sendtner, unpublished results), whereas 
the concentration of NGF is at least 10 000 tirnes lower. 
Given the high biological activity (60 pg CNTF per ml 
medium are sufficient to supportmaximal survival of cul-
tured chick ciliary neurons or motoneurons), it can be 
concluded that only an extremely small proportion of 
available CNTF need be released from Schwann cells to 
influenee responsive neurons. Under pathophysiological 
conditions, when peripheral nerves are lesioned, such low 
quantities of CNTF might become available to the axons. 
Semiquantitative estimations (Table 1) show that the 
quantities of biologicaJly active CNTF in the. distal part 
of a sciatic nerve one week after lesion are still 1000 
times higher than these of NGF, a neurotrophic factor 
whose expression is upregulated in the lesioned nerve 
(Heumann et al. 1987). Interestingly, BDNF synthesis is 
also increased in the lesioned nerve, but with a different 
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Table 1 
Comparison of the Ievels of CNTF and NGF biological activity 
(expressed as trophic units/mg protein) in the sciatic nerve of the 
adult rat after lesion. Data are modified according to Heumannet al. 
(1987) and Sendtner et al. (1992a). 
NGF 
Unlesioned sciatic nerve 0.6 ± 0.2 * 
Distal sciatic nerve 7 days 
after lesion 2.5 ± 0.6 * 
CNTF 
17 500 ± 2 500 * * 
3150± 620** 
* One trophic unit of NGF conesponds to about 75 pglml, which 
is the amount necessary for stimulating half maximal survival 
of embryonie day 8 chick dorsal root sensory neurons in culture. 
** One trophic unit of CNTF conesponds to about 30 pg/ml, the 
amount which supports half maximal survival of embryonie day 
8 chick ciliary neurons in culture. 
time course (Meyer et al. 1992). An increase in BDNF 
mRNA is not detectable until 3 days post-lesion, but dur-
ing the following weeks, BDNF mRNA expression is 
continuously increased up to Ievels which are at least 10 
times higher than those of NGF. By this means BDNF 
might come into play at a time when lesioned mo-
toneurons are regrowing towards their original targets, 
i.e. skeletal muscle. Under pathophysiological condi-
tions, the role of CNTF for lesioned motoneurons might 
be confined to the first days after lesion when early regu-
latory events in the motoneuron cell bodies are detect-
able. Thus at least two factors, CNTF in an early phase 
and BDNF at later stages might interact in regulating the 
regeneration of motoneurons after lesion. 
Furthermore, under normal, physiological conditions 
minute quantities of CNTF might be released from the 
cytoplasm of Schwann cells (e.g. by membrane leakage 
due to microtrauma of the cell membranes) and these 
might act in concert with BDNF, the latter being pro-
duced in very small amounts by skeletal muscle. 
2.3. Action of CNTF in animalmodels for human degenera-
tive motoneuron disease 
A prerequisite for the potential use of neurotrophic 
factor for treatment of neurodegenerative diseases is a 
positive effect of these molecules on motoneuron sur-
vival in vivo. Many agents which have been clinically 
tested in ALS patients in the past did not fulfill this crite-
ria, making the Iack of effect of these substances not sur-
prising (Rowland 1991). 
We have used the pmn mouse mutant as a model for 
testing the effects of CNTF on degenerating neurons. 
This mouse mutant was first described in 1991 by 
Schmalbruch et al. (1991 ). In animals homozygous for 
the gene defect, the disease starts at the endplates. The 
first clinical signs are detectable as weakness of the hin-
dlimbs during the third postnatal week. By the 5th post-
natal week, the disorder has already resulted in the de-
generation of many peripheral motor axons (more than 
70% of the total number of phrenic nerve axons are lost at 
postnatal day 28), and at late stages of the disease (day 
40-42) a significant loss of motoneuron cell bodies is de-
tectable, as measured by the nurober of facial mo-
toneurons in the brain stem of these mice (Sendtner et al. 
1992a). All micedie before postnatal week 7-8, probably 
because of the Joss of functional innervation of the skele-
tal musculature, in particular the diaphragm. 
We have injected embryonie stem (ES) cells stably 
transfected with a CNTF construct containing an N-ter-
minal hydrophobic Ieader sequence to allow secretion of 
CNTF protein from the cells. These cells formed solid tu-
mors after intraperitoneal injection into pmn mice and 
continuously produced high Ievels of CNTF protein 
which could be measured in the blood of these mice. 
pmn/pmn mice treated in this way showed a marked re-
duction of progression of the disease: At postnatal day 
40, when more than 50% of untreated control mice were 
dead, 7 out of 8 CNTF treated mice were still alive. 
Moreover, these mice showed a much better motor per-
formance than their untreated litter mates. This was re-
flected by a significant increase in the numbers of myeli-
nated axons in the phrenic nerve and motoneurons in the 
facial nucleus. A recent report on the effects of CNTF on 
sprouting of motoneurons from endplates and nodes of 
Ranvier (Gurney et al. 1992) is in agreement with these 
Observations. These results indicate that CNTF not only 
Ieads to survival of the motoneuron cell bodies in the spi-
nal cord and brain stem but also prevents axonal and mo-
tor endplate degeneration of these neurons thus leading to 
the improvement of motor function of the treated pmn 
mice. 
2.4. Pharmacokinetics of CNTF after illfravenous injection 
in adult rats 
First attempts with daily subcutaneous injection of 
pmn/pmn mice with 5 ~g of CNTF did not show signifi-
cant effects on the course of the disease. In order to in-
vestigate whether this Iack of effect was clue to rapid 
elimination of CNTF from the circulation, we examined 
the kinetics of 1251-radiolabellecl CNTF after intravenous 
injection into adult rats. Most of the radioactivity was 
eliminated frorn the circulation within a few minutes 
(Dittrich et al., 1994). The same result was obtained when 
unlabelled recombinant rat CNTF was injected into the 
tail vein of adult rats. At different time intervals after in-
travenous injection, the rats were deeply anaesthetizecl 
and blood was taken by cardiaJ puncture. The blood Iev-
els of CNTF, measured by a two-site ELISA, declined 
rapidly within the first 15 min after injection (Fig. 1 ). At 
1 min after injection, only 143 ± 3 ng of CNTF per ml 
blood were measured, indicating that less than 30% of the 
originally injected 5 J..tg of CNTF were detectable in the 
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Fig. 1. Phannacoldnetics of CNTF after intravenous injection inrats. 
5 f.l8 of recombinant rat CN1F was injected into tbe tail vein of adult 
male Wistar rats (200 g body weight). Blood was taken 8fter deep 
ether narcosis by cardiac puncture at 1, 5 and 15 min after CNTF 
injection. Heparin was added. and after centrifugation (10 min at 
1000 g) the Ievels of CNTF were delennined by a 2 site (sandwich) 
ELISA using two non-competing monoclonal antibodies against rat 
CNTF, one of them being coupled to ~-galactosidase. Values shown 
represent mean ± SD from triplicate determinations of blood samples 
from · 3 rats per time point. Recombinant rat CNTF was . used as a 
Standard. Control blood samples from non-injected rat.s did not show 
significant Ievels of CNTF (detection Iimit: 5 nglmlblood). 
circulation (10 ml). After an additional 14 min, CNTF 
concentration per ml of blood declined to 46.7 ± 11 ng, 
which is 32.6% of the Ievel at I min after intravenous in· 
jection. Thus, half-life of CNTF in the blood was 9.4 min, 
using the concentration measured at 1 minute postinjec· 
tion as if a reference. CNTF is rapidly removed from the 
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blood, probably by binding to specific receptors in the 
liver (Dittrich et al., 1994). 
2.5. Theoretical CNTF dose requirements for treatment of 
degenerative diseases of motoneurons 
At present, no data are available as to what dose of 
CNTF would be able to support motoneuron s~rvival and 
function in human degenerative motoneuron disease. The 
diffusion of proteins from the circulation to the endplates, 
which represent the putative uptake site of proteins from 
the blood into motoneurons (Fishman et al. 1991) de-
pends on size and other characteristics of proteins,. and it 
is not clear whether data obtained from rodent animals 
models are representative for the uptake of proteins into 
motoneurons from the circulation in diseased human mo-
toneurons. 
In pmn mice, a serum Ievel of about 500 trophic units 
(TU) ( one trophic unit corresponds to about 20 pg of 
CNTF protein per ml; see Fig. 2) are effective in support-
ing spinal and brainstem motoneurons. These Ievels are 
not directly transferable to humans. The biological activ-
ity of recombinant human CNTF is at least 10 times less 
than recombinant rat CNTF. For half-maximal survival of 
embryonie day 8 chick ciliary neurons about 300.:..500 pg 
of human CNTF are necessary in comparison to about 
10-20 pg of rat CNTF (Masiakowski et al. 1991; our own 
results in Fig. 2). Experiments with human neuroblas-
toma and hepatoma cell lines show a similar ED50 for 
CNTF effects (Huber and Sendtner, unpublished observa-
tions), indicating that the human CNTF protein is also 
less active on human cells. Therefore 500 TU/Illl serum in 
humans would be an equivalent to 150-250 nglml of hu-
man recombinant factor. Such high serum levels would 
/~! 
100 210 1500 30000 
pg I ml medium 
Fig. 2. Dose response curvc for human and rat CNTF. Embryonie day 8 chick ciliary ncurons were cuUurcd in the prescoce of -~ rat 
(1) and lniman (s) CNI'F. Thc numbcr of survivilig neurons (16~3% of thc surface of each dish) were counted under tbe lipt nüctoseöpe after 
24 h in culture. 100~ represents the number of origfnally plated cells (about 1000-2000 neurons per well). Values represent nieail ± SO oflt least 
two (rat CNTF) or 4 (human CNT'f) independent ex:perlments. 
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only be reached when more than 100 J.lg of CNTF per kg 
body weight were to be injected at least once daily into 
patients. 
3. Discussion 
Significant progress has been made in the identifica-
tion of genes which are defective in inherited forms of 
human X-linked bulbospinal muscular atrophy (La Spada 
et al. 1991) and familial amyotrophic lateral sclerosis 
(Rosen et al. 1993). However, it is still open whether the 
great majority of sporadic ALS cases are caused by simi-
lar mechanisms. Differences in clinical and pathological 
appearance suggest that the cellular defects leading to 
loss of motoneuron function might be different. This as-
sumption is also supported by findings in rodent animal 
models: The gene defect of the wobhier mouse, a well-
recognized animal model for motoneuron disease, resides 
on chromosome 11 (Kaupmann et al. 1992)~ in the mnd 
mouse, the defect is on chromosome 8 (Messer et al. 
1992). It appears very likely that the genetic defect in the 
pmn mouse is unrelated to those of wobbler and mnd 
mice. 
The CNTF gene resides on chromosome 19 in the 
mouse (Kaupmann et al. 1991) and on chromosome ll 
(Lam et al. 1991) in man. A defect of this gene has not 
been identified so far as the primary cause of disease in 
any of the known mouse mutants or inherited forms of 
human motoneuron disease. In pmn and wobbler mice, 
biologically active CNTF can be extracted from myeli-
nated peripheral nerves (Kaupmann et al. 1991 ~ Sendtner 
et al. 1992a). In addition, postmartern tissue of human 
ALS patients show normal expression of CNTF mRNA 
and protein, at least in 10 cases which could be analyzed 
(Sendtner, unpublished observations). 
Why should neurotrophic factors such as CNTF be 
useful for treatment of human motoneuron disease, if 
their genes are apparently primarily unaffected in these 
diseases? A large population of motoneurons degenerate 
during embryonie development (for a review see Oppen-
heim 1982) and the mechanism by which these cells are 
eliminated is most probably apoptosis (Raff 1992). If mo-
toneurons from these developmental stages are isolated 
from chick embryos and brought into culture, then they 
degenerate in the absence of appropriate survival factors. 
CNTF, bFGF and IGF-1 are amongst the mostpotent fac-
tors in such cultures of chick embryonie day 6 spinal mo-
toneurons (Arakawa et al. 1990). In the case of CNTF, 
these results were confirmed by in vivo studies when this 
factor was added onto the chorioallantoic membrane of 
chick embryos during the same experimental period (Op-
penhei m 1991). In contrast, bFG F was not acti ve under 
the same experimental conditions (Oppenheim 1992a), 
suggesting that the mechanisms by which these two fac-
tors act on motoneurons are fundamentally different. 
But also in postnatal animals, when nerves are le-
sioned, the subsequent cell death of motoneurons can be 
prevented by the addition of neurotrophic factors such as 
CNTF (Sendtner et al. 1990), BDNF (Sendtner et al. 
1992b; Yan et al. 1992) and, to a lesser extent, NT-3 
(Sendtner et al. 1992b). The differential regulation of 
CNTF and BDNF (Sendtner et al. 1992c; Meyer et al. 
1992) after peripheral nerve lesion suggests that the bio-
logical function of these different factors are not redun-
dant. Furthermore, the different expression patterns of 
BDNF (low but significant amounts in skeletal muscle) 
and CNTF (predominant expression in myelinating 
Schwann cells) suggest that functional maintenance of 
motoneurons is regulated by different factors from differ-
ent cellular sources. The finding that CNTF overexpres-
sion in pmn mice Ieads to significant improvement of mo-
toneuron function (Sendtner et al. 1992a) is an additional 
indicator that this factor is usually not available in abun-
dance to motoneurons. Therefore the pharmacological ap-
plication of CNTF would be justified under conditions 
where motoneurons are degenerating. 
Recent discussions have focussed on the question 
whether the pathological appearance of pmn mice might 
be representative of human motoneuron disease (Vrbova 
et al. 1992). In postmartern tissue of ALS patients, a sig-
nificant loss of spinal motoneurons occurs, the remaining 
cells appear shrunken, dark, with basophilic cytoplasm 
and pyknosis of the nuclei. These morphological charac-
teristics very much resemble the changes occurring dur-
ing apoptosis (for a review see Cohen 1993). Many 
pieces of evidence, such as the finding that more myeli-
nated nerve fibers are detectable in proximal than in dis-
tal parts of motor nerves of ALS patients (Bradley et al. 
1983), have led to the model that ALS starts at the end-
plates, proceeds as degeneration of the axons in a dying 
back-fashion and finally Ieads to degeneration of the cell 
bodies in the spinal cord and brain stem (Chou 1992). 
This would be consistent with the pathological findings 
in pmn mice (Schmalbruch et al. 1991 ). In both cases, 
clinical symptoms are expected to become apparent at the 
stage when motoneuron nerve terminals are affected and 
not after they have died. Based on the effectiveness of 
CNTF in the pmn mouse mutant, this neurotrophic factor 
could indeed interfere with the pathophysiological 
mechanisms leading to functional loss and death of mo-
toneurons in human motoneuron disease. 
Nonetheless, several important questions concerning 
the rational treatment of human motoneuron disease with 
CNTF and other neurotrophic molecules remain open. 
Bolus injection of CNTF Ieads to only very limited avail-
ability of the factor for the motoneurons. It appears likely 
that given the high theoretical doses (more than 100 
J.lg/kg body weight) necessary for reaching sufficient sys-
temic Ievels of the factor, side effects, in particular in the 
liver could preclude this approach from the clinic. Liver 
cells have functional CNTF receptors (Dittrich et al. 
1994) and primary cultures of liver cells have been re-
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ported to react by induction of acute phase proteins after 
CNTF addition (Schooltink et al. 1992; Nesbitt et al. 
1993). This is not unexpected, as the known acute phase 
mediators interleukin·6 and leukemia inhibitory factor in· 
teract with the same receptor subunit (gp 130) as CNTF 
on responsive cells (Taga and Kishimoto 1992; Ip et al. 
1992). It remains to be established whether low doses of 
CNTF which would not Iead to inflammatory responses 
in liver cells are sufficient to support motoneurons in 
ALS patients. Alternative pharmacological approaches 
which would allow increased availability of CNTF for 
motoneurons and reduced side effects might help to over· 
come this problem. Such alternative approaches might 
anyhow be necessary in order to support the upper rno. 
toneurons which are involved in many forms of human 
motoneuron disease. As the neurotrophic requirements of 
these cells are still not known, it remains open whether 
clinical improvement could be reached even in the case 
when maintenance of lower motoneurons would be possi· 
ble. lt remains to be established whether approaches such 
as intrathecal administration (Kroin and Penn 1989; Ochs 
and Struppler 1987) of neurotrophic factors can help to 
overcome these problems or whether new strategies such 
as recombinant viruses for therapeutic gene transfer (An· 
derson 1992) are necessary. 
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